Platelet activation at sites of vascular injury is essential for primary hemostasis, but also underlies arterial thrombosis leading to myocardial infarction or stroke 1,2 . Platelet activators such as adenosine diphosphate, thrombin or thromboxane A 2 (TXA 2 ) activate receptors that are coupled to heterotrimeric G proteins 1,3 . Activation of platelets through these receptors involves signaling through G q , G i and G z (refs. 4-6). However, the role and relative importance of G 12 and G 13 , which are activated by various platelet stimuli 7-9 , are unclear. Here we show that lack of Gα 13 , but not Gα 12 , severely reduced the potency of thrombin, TXA 2 and collagen to induce platelet shape changes and aggregation in vitro. These defects were accompanied by reduced activation of RhoA and inability to form stable platelet thrombi under high shear stress ex vivo. Gα 13 deficiency in platelets resulted in a severe defect in primary hemostasis and complete protection against arterial thrombosis in vivo. We conclude that G 13 -mediated signaling processes are required for normal hemostasis and thrombosis and may serve as a new target for antiplatelet drugs.
G 12 and G 13 constitute a subfamily of heterotrimeric G proteins that are activated through various receptors, including those involved in many platelet stimuli. Mice lacking Gα 13 , the α-subunit of G 13 , die in utero because of a defect in angiogenesis, whereas Gα 12 -deficient mice are phenotypically normal 10, 11 . To circumvent embryonic lethality of mice deficient in Gα 13 and to study the role of Gα 12 -and Gα 13 -mediated signaling in platelet activation, we used Cre/loxP-mediated recombination to conditionally inactivate Gna13, the gene encoding Gα 13 , alone or in a Gα 12 -deficient (Gna12 -/-) background. We generated a Gna13 allele, Gna13 ta , containing three loxP sites and a cassette containing the neomycin resistance (neo r ) and the thymidine kinase gene (tk), by gene targeting of embryonic stem cells (Fig. 1a) . The Gna13 ta allele was converted into a conditional allele, in which exon 2 is flanked by loxP sites (Gna13 flox ), or into a deleted allele (Gna13 − ) by crossing these animals with the Cre-deleter mouse strain EIIa-Cre (ref. 12 ; Fig. 1a-c) . Gna13 flox/flox mice were normal, whereas full recombination of both Gna13 flox alleles results in a phenotype characteristic of the Gna13 -null allele 10 (data not shown).
To generate mice lacking Gα 12 and Gα 13 in platelets, we used a mouse line expressing the Cre gene under the control of the interferon-inducible Mx promoter (Mx-Cre) 13 . Deletion of the Gna13 gene in mice carrying Mx-Cre was induced by intraperitoneal injections of polyinosinic-polycytidylic acid (PIPC). Treatment with PIPC resulted in almost complete recombination in liver, bone marrow and spleen, as assessed by Southern blotting (data not shown). Four weeks after the last PIPC injection, there was no Gα 13 protein detectable in platelets, liver or spleen, whereas levels of other G-protein α-subunits were unchanged ( Fig. 1d and data not shown). Platelet counts were not affected by Gα 13 deficiency, and surface expression of prominent membrane receptors, including glycoprotein Ib-Ix (GPIb-Ix), GPV, GPVI, β 1 and β 3 integrins and CD9, was normal (data not shown).
Because previous studies suggested a role for G 12 and G 13 in the receptor-mediated platelet shape change response 7 , we exposed platelets deficient in both Gα 12 and Gα 13 (Gα 12 /Gα 13 -deficient) to increasing concentrations of various platelet activators. In wildtype platelets, thrombin, collagen and the TXA 2 mimetic U46619 led to platelet shape change at concentrations one to two orders of magnitude lower than those required to induce aggregation. In contrast, there was no shape change in Gα 12 /Gα 13 -deficient platelets in response to low agonist concentrations (Fig. 2a,b and Supplementary Fig. 1 online) . However, at high agonist concentrations, Gα 12 /Gα 13 -deficient platelets underwent shape change and all stimuli induced aggregation, although with considerably lower potency than in wild-type platelets. Surprisingly, platelets lacking only Gα 13 showed defects indistinguishable from those observed in Gα 12 /Gα 13 -deficient platelets, whereas platelets lacking only Gα 12 behaved like wild-type. Thus, Gα 13 , but not Gα 12 , is required for the induction of shape change and aggregation in response to low and intermediate concentrations of TXA 2 , thrombin and collagen.
To test whether the aggregation defect observed in Gα 13 and Gα 12 /Gα 13 -deficient platelets was caused by defective inside-out activation of α IIb β 3 integrin, we directly assessed this process by flow cytometry. Because this analysis was conducted in diluted platelet suspensions, which largely excludes the accumulation of released mediators, U46619 does not lead to significant α IIb β 3 activation and degranulation unless G i -type G proteins are activated by coadministration of adrenaline or adenosine diphosphate 14 . Thrombin-induced α IIb β 3 activation was indistinguishable between wild-type and Gα 12 /Gα 13 -deficient platelets, and there was only a very small decrease in Gα 13 and Gα 12 /Gα 13 -deficient platelets, as compared with wild-type and Gα 12 -deficient platelets, when exposed to U46619 in the presence of adrenaline (data not shown). Thus, the defective aggregation response of Gα 13 -and Gα 12 /Gα 13 -deficient platelets is not caused by impaired inside-out activation of α IIb β 3 .
We next examined whether the absence of Gα 12 , Gα 13 or both had any effect on platelet degranulation. Whereas U46619-or adrenaline-induced P-selectin exposure and serotonin secretion was markedly reduced in Gα 13 ( Fig. 2c and data not shown), thrombin-induced secretion was not affected by Gα 12 and/or Gα 13 deficiency (data not shown).
Thrombin exerts its effects on mouse platelets primarily through the protease-activated receptor (PAR)-4 (ref. 15 ). P-selectin exposure and serotonin secretion in response to the PAR-4-activating peptide AYPGKF was clearly reduced in platelets lacking Gα 13 ( Fig. 2d) . This suggests that thrombin induces additional, PAR-4-independent signaling pathways that compensate for the lack of Gα 12 and/or Gα 13 in the degranulation response, but not in aggregation and shape change. GPIb, which has a role in thrombininduced activation processes 16 , does not seem to be involved, as proteolytic removal of the 45-kDa N-terminal ligand-binding domain of GPIb-α did not affect the ability of thrombin to induce secretion in Gα 13 -deficient platelets (data not shown).
Because the Rho-and Rho kinase-mediated signaling pathway leading to myosin light chain (MLC) phosphorylation is activated through G 12 and G 13 together (ref. 17) , and because Rho and Rho kinase are involved in the induction of platelet shape change 7, 18, 19 , we tested whether activation of RhoA and phosphorylation of MLC were affected in Gα 12 /Gα 13 -deficient platelets. In wild-type platelets, U46619 induced RhoA activation and MLC phosphorylation, with a maximal effect at 10 nM. Again, Gα 12 -deficient platelets were indistinguishable from wild-type platelets in this regard. In Gα 12 /Gα 13 -or Gα 13 -deficient platelets, however, no RhoA activation or MLC phosphorylation was observed in response to 10 nM U46619 (Fig. 3a) , indicating that RhoA activaa b c d tion and subsequent MLC phosphorylation is primarily induced through G 13 in platelets. We next studied the potential role of the G 13 -mediated signaling pathway in thrombus formation during perfusion of whole blood over collagen under high shear conditions ex vivo (Fig. 3b) . Wildtype and Gα 12 -deficient platelets adhered to collagen fibers, and adherent platelets initiated the formation of platelet aggregates within 2 min. Initial adhesion of Gα 13 -or Gα 12 /Gα 13 -deficient platelets was indistinguishable from that observed with wild-type platelets. However, platelet thrombus formation was severely impaired, and virtually no thrombi could be observed after rinsing the chamber (Fig. 3b-d) . These findings suggest that the formation and stabilization of platelet thrombi under high shear flow conditions requires intact signaling through the G 13 -mediated pathway. The defective activation of RhoA in the absence of G 13 may contribute to the observed defect in the formation of stable platelet aggregates, as RhoA may be required for platelet aggregation under high shear conditions and for irreversible aggregation of platelets in suspension 20, 21 .
To test whether defects observed in Gα 13 -and Gα 12 /Gα 13 -deficient platelets in vitro would have any effect under in vivo conditions, we determined tail-bleeding times as a measure for primary hemostasis (Fig. 4a) . Mice with Gα 13 -or Gα 12 /Gα 13 -deficient interferon-responsive tissues had massively increased bleeding times compared with wild-type or Gα 12 -deficient mice (Fig. 4a) . To rule out the possibility that Gα 13 deficiency in endothelial cells, hepatocytes or other interferon-responsive organs contributed to the increased bleeding time, we restricted the Mx-Cre-induced deletion of Gna13 to the hematopoietic system by transferring bone marrow cells derived from PIPC-induced Mx-Cre Gna12 -/-Gna13 flox/flox or Mx-Cre Gna13 flox/flox mice into irradiated wild-type recipient animals. Four weeks after the transfer, all transplanted animals had normal platelet counts, but bleeding times of mice transplanted with Gα 13 -or Gα 12 /Gα 13 -deficient bone mar- row were massively prolonged (>20 min) compared with mice transplanted with bone marrow from noninduced Mx-Cre Gna12 +/+ Gna13 flox/flox mice (Fig. 4b) . This indicates that G 13 -mediated signaling is required for normal hemostasis. We next assessed the role of Gα 13 in arterial thrombus formation by in vivo fluorescence microscopy of the injured carotid artery. The experiment was conducted using wild-type animals transplanted with wild-type or Gα 13 -deficient bone marrow. After induction of injury by ligation of the carotid artery, wild-type platelets adhered to the subendothelial surface and massive thrombi subsequently developed in the carotid artery (Fig. 4c-e) . Platelets lacking Gα 13 also adhered rapidly to the injured vessel wall (Fig. 4c) . However, the total number of platelets that firmly adhered was reduced by ∼50% compared with wild-type platelets. In contrast to wild-type animals, mice with Gα 13 -deficient platelets did not show any thrombi after vascular injury, indicating that Gα 13 -deficient platelets were not able to form stable thrombi in vivo (Fig. 4d,f) . This is consistent with the data obtained ex vivo and shows that the initial adhesion of platelets to the injured vessel wall was not substantially altered, whereas the subsequent formation and stabilization of platelet thrombi was altered by the absence of G 13 -mediated signaling.
Platelet activation during hemostasis and thrombosis is a complex process involving many stimuli that act on platelets at sites of vascular injury. Most of these stimuli directly or indirectly use Gprotein-mediated signaling pathways to induce platelet activation. Defining the relative importance of signaling through different heterotrimeric G proteins is useful in understanding the molecular mechanisms of platelet activation. Our data clearly indicate that G 13 -mediated signaling is necessary for platelet activation in hemostasis and thrombosis. Whereas the phenotypic changes in platelets from Gα i2 -or Gα z -deficient mice seem to be less severe 6, 22, 23 , the defects observed in mice with Gα 13 -deficient platelets are comparable with the in vivo defects in mice lacking Gα q (ref. 4). Thus, platelet activation seems to be an integrated process that requires different G-protein signaling pathways involving G q , G i , G z and G 13 . Although signaling through two of these pathways can be sufficient to induce some platelet activation 5, 14, 24 , all three pathways seem to be required for efficient platelet activation under physiological and pathological conditions. The severe defects observed in mice with Gα 13 -deficient platelets may be caused by the decreased responsiveness of Gα 13 -deficient platelets to various stimuli. Reduced potency of platelet activators may become limiting, especially under high flow conditions that lead to rapid clearance of soluble stimuli. We also observed impaired stabilization of platelet thrombi under high shear stress, a process that may require acute and continuous activation of RhoA-mediated signaling pathways. The fact that Gα 13 deficiency protected animals against thrombosis suggests that inhibition of the G 13 -mediated signaling pathway in platelets is a promising strategy to prevent or treat platelet activation in thrombosis.
METHODS

Conditional inactivation of the Gna13 gene. See Supplementary Methods online.
Western blot analysis. Platelet lysates were subjected to SDS-PAGE. After blotting, nitrocellulose membranes were probed with antibodies to Gα 12 (ref. 25) and to Gα 13 , Gα i and Gα q/11 (Santa Cruz Biotechnology).
Platelet preparation and aggregation. All animal experiments and care were approved by the local Animal Care & Use Committee. Whole blood was collected from the retro-orbital plexus in acid citrate dextrose (150 µl per ml blood) from anesthetized mice. Blood was diluted with half the volume of HEPES-Tyrode buffer [137 mM NaCl, 2 mM KCl, 12 mM NaHCO 3 , 0.3 mM NaH 2 PO 4 , 2 mM CaCl 2 , 1 mM MgCl 2 , 5.5 mM glucose and 5 mM HEPES (pH 7.3)] containing 0.35% human serum albumin. Platelet-rich plasma was washed once, and optical aggregation experiments were conducted in a two-channel aggregometer (Chrono-Log).
Flow cytometry. Washed platelets (2 × 10 6 ) were incubated with the indicated stimuli for 2 min at 37 °C, stained with fluorophore-conjugated monoclonal antibodies (emfret Analytics) at saturating concentrations for 15 min at room temperature and directly analyzed on a FACSCalibur (Becton Dickinson). Platelets were gated by forward and side scatter 14 . Determination of activated cellular Rho and MLC phosphorylation. The amount of activated cellular Rho was determined by precipitation with a fusion protein consisting of glutathione-S-transferase (GST) and the Rhobinding domain of rhotekin (GST-RBD) 26 . Platelets were stimulated with 10 nM of U46619 for 10 s, lysed and subjected to GST-rhotekin pull-down. Precipitated GTP-bound RhoA and lysates were immunoblotted with antibodies against RhoA, MLC or the phosphorylated form of MLC (all from Santa Cruz Biotechnology).
Secretion
Flow chamber experiments. Experiments were conducted as described 27 . Briefly, transparent flow chambers with a slit depth of 50 µm, equipped with Horm-type collagen-coated cover slips, were connected to a syringe filled with anticoagulated blood. Perfusion was done using a pulse-free pump under high shear stress equivalent to a wall shear rate of 1000 s -1 (4 min). The chambers were then rinsed with a 4 min perfusion of HEPES buffer containing 2 mM Ca 2+ , at the same shear stress, and phase-contrast images were recorded from at least five different microscope fields (×40 objectives). Shown are experiments representative of five to eight experiments per group.
Determination of bleeding times. Adult mice were anesthetized with intraperitoneal pentobarbital (50 mg per kg body weight) and intramuscular xylazin (3 mg/kg), and the tail was cut 5-6 mm from the tip and immersed in saline at 37 °C. Bleeding time was defined as the time at which all visible signs of bleeding from the incision had stopped. The experiment was stopped after 20 min.
Carotid artery ligation and assessment of platelet adhesion and aggregation. Experiments were conducted as described 28 . Platelets were isolated and labeled with 5-carboxyfluorescein diacetate succinimidyl ester as described. Labeled platelets (200 × 10 6 platelets per 250 µl) were infused intravenously into anesthetized mice of the same genotype as those used to prepare the platelets. The right common carotid artery was dissected free and ligated vigorously near the carotid bifurcation for 5 min to induce vascular injury. Adhesion of autogeneous platelets was assessed before and after carotid injury by in vivo video microscopy 28 . Videotaped images were evaluated using a computer-assisted image analysis program 28 (Cap Image 7.4, H. Zeintl). The number of adherent platelets was assessed by counting the cells that did not move or detach from the endothelial surface within 10 s. The area covered by thrombi was also quantified and is presented in µm 2 .
Histology. Carotid arteries were perfusion-fixed in situ with 4% paraformaldehyde (pH 7.0) 15 min after induction of injury, excised, fixed in 0.1 M cacodylate-buffered Karnovsky solution (2.5% glutaraldehyde and 1% paraformaldehyde) overnight at room temperature and postfixed in 1% osmium tetroxide for 2 h at pH 7.3. The samples were dehydrated in graded ethanols and embedded in EmBed-812 epoxy resin (all reagents from Science Services). After 48 h of heat polymerization at 60 °C, semithin (0.8 µm) sections were cut with a diamond knife (Diatome) and double stained with aqueous solutions of 1% toluidine blue and basic fuchsin (60 °C, 1 min).
Bone marrow transplantation. Bone marrow cells from mice (10-12 weeks old) were removed aseptically from femurs and tibias. Cells (5 × 10 6 ) were resuspended in DMEM and transplanted by tail-vein infusion into lethally irradiated (10 Gy) recipients (C57BL/6; Charles River) 1 d after irradiation. Gα 13 deficiency was verified by western blotting.
